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Anthracyclines are one of the most widely 
studied drugs in terms of cardiotoxicity, 
and are a mainstay component of anti-
cancer regimens. Not only do one-third of 
those with cancer have hypertension, but 
it is also the most commonly reported 
comorbidity in cancer registries. In order 
to provide optimal treatment for the health 
of the growing population of cancer 
patients with hypertension comorbidity, it 
is necessary to understand the potential 
effects, if any, their hypertension and 
anthracycline treatment will have on 
short- and long-term cardiac function. 
• To assess whether anthracycline 
chemotherapy exacerbates cardiotoxicity 
in patients with hypertension comorbidity.
• To describe its molecular and 
pathophysiologic mechanisms 
• To identify novel therapeutic modalities 
to combat potential exacerbation 
• We summarize evidence from the literature 
as well as animal models that support the 
claim that hypertension does indeed 
worsen the cardiotoxic effects of anti-
cancer chemotherapeutic drugs. 
• Management should rest upon a careful 
balance of risks and benefits. Meticulous 
attention should be paid on pretreatment 
screening for risk factors, robust monitoring 
of cardiac function, and early intervention 
for preexisting comorbidities. 
• In nearly all cases, it is recommended to 
first manage the patient’s hypertension 
before administering anthracycline 
treatment. 
• Cardioprotectants (i.e. dexrazoxane) 
should be explored as a viable solution on 
a case-by-case basis. 
We performed a literature search using 
the Medline database on Pubmed on all 
articles addressing the relationship of 
anthracycline cardiotoxicity and 
hypertension. 
Figure 1: Diagrammatic summary of the vicious cycle for cardiovascular pathology under the 
comorbidity of anthracycline cardiotoxicity and hypertension. The current and potentially promising 
novel therapeutic strategies are also indicated. Abbreviations: LV – left ventricular; ACEI –
angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker. 
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Figure 2: Summary of mechanistic overlap of anthrayclines and hypertension. 
• Von Hoff et al. reported 
the earliest link between 
hypertension and 
doxorubicin cardiotoxicity 
through a retrospective 
analysis of 4018 patients 
in cooperative group trials 
(Von Hoff et al., 1979). 
• The results of a study by 
Herman et al. 
demonstrate that 
hypertensive rats were 
more prone to cardiac 
damage by doxorubicin 
than the normotensive 
rats (Herman et al., 1985). 
• Even when compared to 
hypertension comorbidity, 
total cumulative dose still 
remains the most 
significant and major risk 
factor for anthracycline-
related CHF. 
• As demonstrated in Figure 
1 and Figure 2, a 
pathophysiologic overlap 
exists between 
hypertension and 
anthracycline in terms of 
cardiotoxicity.
• As the mean age of the population 
increases, and concurrently the risk of 
hypertension and cancer, cardio-
oncologists are needed to effectively 
satisfy the management of a growing 
subgroup of patients.
• Further research is needed to aid in the 
clinical management of these patients. For 
example, little information is available on 
dosing adjustments and follow-up 
scheduling. Additionally, combinations of 
anticancer drugs are increasingly being 
used to aggressively treat various forms of 
cancer. While these drugs have various 
cardiac implications, it is important to 
investigate the potential additive or 
interactive effects of these drugs.
